Kiniksa outlines $900M-$920M 2026 ARCALYST revenue guidance as market penetration deepens
Source: SeekingAlpha
2026-02-24 11:19:01 ET
More on Kiniksa Pharmaceuticals International, plc
- Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
- Kiniksa Pharmaceuticals International, plc 2025 Q4 - Results - Earnings Call Presentation
- Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator
- Kiniksa Pharmaceuticals International reports mixed Q4 results; introduces FY26 outlook
- Kiniksa Pharmaceuticals International, plc Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Kiniksa outlines $900M–$920M 2026 ARCALYST revenue guidance as market penetration deepens
Kiniksa Pharmaceuticals Ltd.
NASDAQ: KNSA
KNSA Trading
-1.98% G/L:
$45.25 Last:
74,063 Volume:
$45.87 Open:
KNSA Latest News
February 25, 2026 04:01:00 pm
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026 07:30:00 am
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
KNSA Stock Data
$3,390,723,279
40,262,707
0.03%
71
N/A
Biotechnology & Life Sciences
Healthcare
BM
London
